



## Molecular detection of john cunningham virus (JCV) in patients with colorectal cancer in khartoum, Sudan

Eman I Mohamed<sup>1</sup>, Abdel Rahim M El Hussein<sup>2</sup>, Isam M Elkhidir<sup>3</sup>, Khalid A Enan<sup>4\*</sup>

<sup>1</sup> Department of Medical microbiology, Faculty of Medical Laboratory Science, El Nellin University, Khartoum, Sudan

<sup>2,4</sup> Department of Virology, Central Laboratory- The Ministry of Higher Education and Scientific Research, Khartoum, Sudan

<sup>3</sup> Department of Microbiology and Parasitology, Faculty of Medicine, University of Khartoum, Khartoum, Sudan

### Abstract

**Background:** Colorectal cancer (CRC) is the most repetitious malignancies with high mortality worldwide. JC virus (JCV) is ubiquitous Polyomavirus, with seroprevalence rates ranging from 70% to 90% in adult population. Recently the roles of JCV have been reported in many malignant tumors worldwide. The association of JCV was reported in patients with colon and rectum cancers

**Objective:** the study was conducted to evaluate the association of JCV DNA in patients with colorectal cancer in Khartoum State.

**Materials and methods:** A total of 70 formalin-fixed paraffin-embedded tissue block samples were collected including 33 (47.1%) male 37(52.9%) female patients with CRC. DNA was extracted from all the samples. Nested PCR was carried out for detection of Vp1/T Ag junction genome in JCV genome by Nested-PCR assay.

**Results:** 3/70(4.2%) samples of patients were positive for JCV DNA (P 0.522). Out of 3 samples positive for JC DNA, 2(2.8%) were males and 1(1.4%) was female.

**Conclusion:** prevalence of JCV DNA was 4.2% among patients with CRC. Including 2.8% male and 1.4% female (p= 0.522). The subsequent T-Ag protein expression might explain the increased risk of colorectal cancer and requires further investigation

**Keywords:** JC virus- colorectal cancer- polymerase chine reaction

### Introduction

Colorectal cancer (CRC) is the most recurrent malignancy, and third leading cancer with high mortality among men and women worldwide [1]. The pathogenesis of this tumor is not well known. Predisposing factors include Crohn's disease, celiac disease, hereditary genetic syndromes and dietary factors [2]. JCV is associated with disease primarily in immune compromised individuals and its replication in glial cells could lead to progressive multifocal leukoencephalopathy (PML), an often-fatal disease of central nervous system [3]. More recently, JCV was also found in non-neural cancers, such as gastric [4] and lung cancers [5]. JCV infection was first reported as a potential risk factor for colorectal cancer (CRC) in a work by Laghi *et al.* [6], which found that 96% of CRC tissues were positive for JCV DNA sequences. Subsequently, other studies have been published showing that JCV sequences were found in 26%–88.9% of CRC tissues [7, 10].

The John Cunningham virus (JCV) is a ubiquitous, small, non-enveloped polyomavirus with a closed, circular, double-stranded DNA genome that frequently resides in the kidneys of healthy individuals and is excreted in the urine of a large portion of the adult population. JCV infection is subclinical and leads to lifelong latency, but may be reactivated when the immune system is impaired [11, 13]. About 90% of the adult population carries antibodies to the virus, and it seems that in most people, the virus remains latent [14]. High concentrations of JCV have been observed

in urban sewage worldwide; therefore, it is suspected that the contaminated water is a typical route of JCV infection [15]. JCV encodes three proteins that are the structural capsid proteins: VP1, VP2, and VP3 [16]. JCV also encodes the T antigen proteins (i.e., Large T and multiple small t splice variants) and the agnoprotein which is involved in the assembly of viral particles. T-Ag has several splice sites producing truncated proteins that are involved in regulating cell proliferation and viral transmission [17]. Like other polyomaviruses, JCV encodes a version of a large T-antigen that can bind to and inactivate tumor suppressor proteins p53 and pRB and interfere with several cell-signaling pathways [18, 20]. Moreover, JCV genomic DNA sequences and T-antigen expression have been detected in a broad range of tumor cell types including oligodendrocytes, astrocytomas, glioblastomas, ependymomas, and most other types of brain tumors, indicating that JCV infection may be associated with human carcinogenesis [21]

Studies on association of JCV and colorectal in Sudan is limited, therefore, this study was conducted to evaluate the rate of JCV in patients with CRC in Khartoum city.

### Material and Method

#### Sample preparation

A total of 70 formalin-fixed paraffin-embedded tissue blocks samples were collected from 70 patients including 33(51.4%) males and 37(48.6%) female patients (mean age –55) with CRC during May 2018 to May 2019.

**Deparaffinization**

Deparaffinization was done using xylene and ethanol (Germany, Merk). Initially, all the specimens were placed in microtubes then xylene was added and kept at 45oC for 15 min followed by centrifugation at 14,000 rpm. This step was repeated once more and the supernatant was discarded and 1ml absolute ethanol was added to precipitate and stored at the room temperature for 10 min and centrifuged again at 14,000 rpm for 1 minute. The supernatant was discarded. This process was repeated by adding 70% ethanol, followed the same condition. Finally, supernatant was discarded and all microtubes were placed at 65oC for 5 min to vaporize the ethanol residue and the pellet was used in DNA extraction (Bouzari M, The 4th national Biotechnology Congress Islamic Republic of Iran; 2005)

**DNA extraction**

DNA extracted from deparaffinized tissue by guanidine chloride (Black-well laboratory Cambridge, UK) as follow: samples were subject to lyses solution containing 400mMNaCl, 6M guanidine chloride and 300 µl of 7.5% ammonium acetate and heat treated at 98°C for 20 minutes in water bath. After cooling 10µl (20 mg/ml stock) proteinase K was added and incubated for overnight at 56°C. On day two, second heat treatment was applied by incubating samples at 98 °C for 5 minutes in a water bath. After cooling 10µl proteinase k was added, briefly vortexed and incubated at 56 °C for overnight. During the whole incubation period samples were put on a shaker at interval for about 30 minutes. Chloroform was then added, the supernatant was collected, and DNA was precipitated by ethanol, dissolved in 100 µl TE storage buffer. The purity and quality of the extracted DNA was analyzed based on absorbance of the extracted DNA at 260 and 280 nm wavelengths using a spectrophotometer (NanoDrop-1000, Thermo Fisher Scientific, and Wilmington, USA)

**Semi-nested PCR assay to detect JCV DNA**

The semi nested PCR was carried out as described in [22] using three primers to amplify JCVT-antigen sequences as follows: T-antigen: T1 (TGGCCTGTAAAGTTCTAGGCA) and T2 (GCAGAGTCAAGGGATTACCTTC) and Second PCR amplification was conducted using sets of primers for T1 and T3 (AGCAACCTTGATTGCTTAAGAGA) [23]. Three primers display sequences that avoid annealing with Polyomaviruses other than JCV nucleotides. Each reaction was performed in 25 µl volume containing 5 µl master mix, 1 µl of each primer (1 and 2) for the first round and (1 and 3) for the second round, 7 µl of DNA, and 11 µl of distilled water. Reactions were performed using PCR machine under the following cycling conditions: 8 min at 95°C followed by 35 cycles of 30 s at 95°C, 30 s at 55°C and 30 s at 72°C. A final elongation period of 7 min at 72°C was applied. 5 µl of the PCR product was analyzed by gel electrophoresis in 2% Agarose, and stained with 0.15% Ethidium bromide and the product was visualized by using UV gel documentation system INGeNius Germany. The expected size of JCV DNA amplicon is 145 bp.

**Statistical analysis**

Collected data were analyzed using statistical package for social science (SPSS version 16.0). A p value of ≤ 0.05 was considered significant.

**Result**

In this investigation 3/70(4.2%) samples of CRC were positive for JCV. 2/36 (5.5%) were from male patients while 1/34 (1.4%) was from a female patient with (p=0.589) and of the age groups 41–60 yrs. (Tables 1 and 2). There was no significant association between gender and prevalence and JCV positivity

**Table 1:** Frequency of positive result according age group

		Age							Total
		10 - 20	21 - 30	31 - 40	41 - 50	51 - 60	61 - 70	71 - 80	
result	positive	0	0	0	2	1	0	0	3
	negative	5	7	10	14	12	12	7	67
Total		5	7	10	16	13	12	7	70

**Table 2:** Frequency of positive result according to gender

		Sex		Total
		Male	Female	
Result	Positive	2	1	3(4.2%)
	Negative	34	33	67(95.8%)

**Discussion**

CRC is one of dominant cause of death among man and women worldwide. Several viruses were suggested to be the risk factors for CRC. Among them, JC virus, BK virus, Human Cytomegalovirus (CMV), Human papilloma viruses (particularly type 16 and 18) have the largest number of report [24]. High prevalence of 82% and 90% of JC virus associated colorectal carcinoma have been reported in Portugal and USA respectively [25, 26]. In the present study 4.2% of our CRC patients were positive for JCV DNA in agreement with results reported by Mou *et al.*, (2012) in China [27]. Sarvari *et al.*, (2018) have reported low prevalence of 1.42% JCV DNA in patients with CRC, in Shiraz city, Iran, which was lower than our finding [28]. In the present study the rate of JCV DNA was among the male (2.8%) and female (1.4%) patients in contrast to Shalaka *et al.*, (2014), who reported that the rate of JCV in male patients with CRC is higher than in females [26]. Recent investigations revealed that, infected patients with JC virus in immunodeficiency status may results in progress to PML, thus, treatment of patients infected with JC virus by rituximab natalizumab and efalizumab lead to progressive multifocal leukoencephalopathy. Therefore, it is suggested that the urine of patients with CRC cancer or patients with autoimmune diseases should be screened for JC virus DNA before chemotherapy treatment or by immunomodulatory drugs (rituximab and natalizumab) therapy [29, 30].

**Conclusion**

In the present study 4.2% of our study population was found positive for JCV using nested PCR, and no significant differences according to age and sex were discernable. Our present study also represents the first report on JCV infection in colorectal patients in Sudan.

**Ethical review**

The study was approved by the Ethical Review Committee (ERC) of Alneelain University, the Ministry of Higher Education & Scientific Research, Khartoum State, Sudan.

**References**

1. World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Continuous Update

- Project Report Diet, Nutrition, Physical Activity and Colorectal Cancer, 2016. Revised 2018. London: World Cancer Research Fund International. [aicr. Org/continuous-update-project/ reports/colorectal- cancer-2017-report.pdf](http://aicr.org/continuous-update-project/reports/colorectal-cancer-2017-report.pdf). Accessed June 21, 2018
2. Zaaimi Y, Aparicio T, Laurent-Puig P. Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives. *Clin Res Hepatol Gastroenterol*. 2015; 40:154-60.
  3. Berger JR. The basis for modeling progressive multifocal leukoencephalopathy pathogenesis. *Curr Opin Neurol*. 2011; 24:262-267.
  4. Ksaa F, Ziadi S, Mokni M, Korbi S, Trimeche M. The presence of JC virus in gastric carcinomas correlates with patient's age, intestinal histological type and aberrant methylation of tumor suppressor genes. *Mod Pathol*. 2010; 23:522-530.
  5. Abdel-Aziz HO, Murai Y, Hong M, Kutsuna T, Takahashi H. Detection of the JC virus genome in lung cancers: possible role of the T-antigen in lung oncogenesis. *Appl Immunohistochem Mol Morphol*. 2007; 15:394-400.
  6. Laghi L, Randolph AE, Chauhan DP, Marra G, Major EO. JC virus DNA is present in the mucosa of the human colon and in colorectal cancers. *Proc Natl Acad Sci U S A*. 1999; 96:7484-7489.
  7. Casini B, Borgese L, Del Nonno F, Galati G, Izzo L. Presence and incidence of DNA sequences of human polyomaviruses BKV and JCV in colorectal tumor tissues. *Anticancer Res*. 2005; 25:1079-1085.
  8. Hori R, Murai Y, Tsuneyama K, Abdel-Aziz HO, Nomoto K. Detection of JC virus DNA sequences in colorectal cancers in Japan. *Virchows Arch*. 2005; 447:723-730.
  9. Enam S, Del Valle L, Lara C, Gan DD, Ortiz-Hidalgo C. Association of human polyomavirus JCV with colon cancer: evidence for interaction of viral T-antigen and beta-catenin. *Cancer Res*. 2002; 62:7093-7101.
  10. Theodoropoulos G, Panoussopoulos D, Papaconstantinou I, Gazouli M, Perdiki M. Assessment of JC polyoma virus in colon neoplasms. *Dis Colon Rectum*. 2005; 48:86-91.
  11. Rollison DE, Helzlsouer KJ, Alberg AJ, Hoffman S, Hou J. Serum antibodies to JC virus, BK virus, simian virus 40, and the risk of incident adult astrocytic brain tumors. *Cancer Epidemiol Biomarkers Prev*. 2003; 12:460-463.
  12. Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. *J Infect Dis*. 1973; 127:467-470.
  13. Reiss K, Khalili K. Viruses and cancer lessons from the human polyomavirus, JCV. *Oncogene*. 2003; 22:6517-6523.
  14. Knowles WA. Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). *AdvExp Med Biol*. 2006; 577:19-45
  15. Dias J, Pinto RN, Vieira CB. Detection and quantification of human adenovirus (HAdV), JC polyomavirus (JCPyV) and hepatitis A virus (HAV) in recreational waters of Niterói, Rio de Janeiro, Brazil. *Mar Pollut Bull*. 2018; 133:240-5.
  16. Zheng HY, Takasaka T, Noda K. New sequence polymorphisms in the outer loops of the JC polyomavirus major capsid protein (VP1) possibly associated with progressive multifocal leukoencephalopathy. *J Gen Virol*. 2005; 86:2035-45.
  17. Frisque RJ. Structure and function of JC virus T' proteins. *J Neurovirol*. 2001; 7:293-7
  18. Gan DD, Khalili K. Interaction between JCV large T-antigen and beta-catenin. *Oncogene*. 2004; 23:483-490.
  19. Trojanek J, Croul S, Ho T, Wang JY, Darbinyan A. T-antigen of the human polyomavirus JC attenuates faithful DNA repair by forcing nuclear interaction between IRS-1 and Rad51. *J Cell Physiol*. 2006; 206:35-46.
  20. Reiss K, Khalili K, Giordano A, Trojanek J: JC virus large T-antigen and IGF-I signaling system merge to affect DNA repair and genomic integrity. *J Cell Physiol*. 2006; 206:295-300.
  21. Caldarelli-Stefano R, Boldorini R, Monga G, Meraviglia E, Zorini EO. JC virus in human glial-derived tumors. *Hum Pathol*. 2000; 31:394-395.
  22. Bofill MS, Pina S, Girones R. Documenting the epidemiologic patterns of polyoma viruses in human populations by studying their presence in urban sewage. *Appl Environ Microbiol*. 2000; 66:238-245.
  23. Jian PW, Zuo ZW, Yu SZ, Xia P, Xiang HY. JC virus existence in Chinese gastrointestinal carcinomas. *Oncol Lett*. 2012; 3:1073-1078.
  24. Vlado A, Alexander S, Kent E. Significance of infectious agents in colorectal cancer development. *J Cancer*. 2013; 4:227-4.
  25. Coelho TR, Gaspar R, Figueiredo P. Human JC polyomavirus in normal colorectal mucosa, hyperplastic polyps, sporadic adenomas, and adenocarcinomas in Portugal. *J Med Virol*. 2013; 85:2119-27
  26. Shalaka S, Hampras F, Raphael P. Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas cancer. *Epidemiol Biomarkers Pre*. 2014; 23:2591-6.
  27. Mou X, Chen L, Liu F. Prevalence of JC virus in Chinese patients with colorectal cancer. *PLoS One*. 2012; 7:e35900.
  28. Sarvari J, Mahmoudvand S, Pirbonyeh N. Very low frequency of Epstein-Barr JC and BK viruses' DNA in colorectal cancer tissues in Shiraz, Southwest Iran. *Pol J Microbiol*. 2018; 67:73-9
  29. David B, Clifford Beau A, Craig C. Rituximab associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. *Arch Neurol*. 2011; 681:156-64.
  30. McGuigan CM, Craner J, Guadagno. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. *J Neurol Neurosurg Psychiatry*. 2016; 87:117-125.